A doctor's torso behind the words Cancer Research with a blue background.

Is precision oncology really that much better than conventional cancer care? The answer is, Yes! The survival rates for stage IV cancer are significantly better with CTOAM’s precision oncology process. 

And here are the statistics to prove it.  

In the following graph and tables, we outline the overall significant increase in survival rates for stage IV cancer that our patients experience in contrast to those seen with conventional/standard Canadian cancer care. 

Live Longer with Precision Oncology

The patients listed have had at least one or more of CTOAM’s recommended therapies. Additionally, the patient data used for this chart comes from clients who were all determined to be stage IV at the time they reached out to bring us on board.

It is possible, if not probably, that patients may have been at stage IV for a significant period of time before CTOAM’s involvement, and this can lead to an underestimation the benefits of our recommended interventions. Meaning, had these patients come to us at the time of their first diagnosis, or before their cancer reached Stage IV, it is highly likely these long-term survival time numbers would be significantly higher, which is exactly what we see with those who do reach out at the sign of initial symptoms and early diagnosis.

For Stage IV cancer patients who have been told there is only one option, or perhaps even no options, knowing that treatments are available, often within the Canadian cancer care system and from their own Oncologist at home, can be a crucial lifeline. The treatment options we find for our patients have all been proven, in peer-reviewed, Oncology journals, to be providing better results than standard care. 

Yes! CTOAM’s Precision Oncology program has significantly Better Survival Rates than Standard Care

The standard survival rates below refer to the conventional therapies offered to the patients by their public health care system oncologists at the time of CTOAM’s intervention. The first table refers to Stage IV patients of any cancer type; the second refers specifically to Stage IV patients with colon cancer.

Graph showing that precision oncology and CTOAM offers higher survival rates than standard cancer care.

CTOAM Patient Survival Statistics (2018)

Table 1: Survival Rates of Stage IV CTOAM Patients compared to Standard (Prescribed) Treatment Rates

Type of Cancer Date of Diagnosis Standard Overall Survival Actual Survival Time Increased Survival Time with CTOAM
Colon 01/12/2013 15.3 mths (1) 52.0 mths (to date) 36.7 mths (240%)
Melanoma 01/09/2013 5.6 – 11.0 mths (2) 55.0 mths (to date) 44.0 mths (400-786%)
Lung 13/09/2014 7.7 mths (3) 20.0 mths 12.3 mths (160%)
Breast 01/03/2015 11.0 mths (4) 35.0 mths 24.0 mths (218%)
Gynecological 18/12/2012 30.7 mths (5) 51.0 mths 20.3 mths (66%)

Table 2: Survival Rates of Stage IV CTOAM Colon Cancer Patients compared to Standard (Prescribed) Treatment Rates

Patient Age Date of Diagnosis Standard Overall Survival Actual Survival Time Increased Survival Time with CTOAM
45 yrs 01/04/2013 15.3 mths (1) 23.0 mths 7.7 mths (50%)
53 yrs 01/12/2013 15.3 mths (1) 52.0 mths 36.7 mths (240%)
64 yrs 01/01/2014 15.3 mths (1) 27.0 mths 11.7 mths (76%)
64 yrs 01/06/2015 10.4 mths (6) 28.0 mths 17.6 mths (169%)

Hope for Cancer Patients is Here

As you can see, CTOAM offers significantly increased survival times for Stage IV cancer patients compared to standard treatment. Not only did these patients live longer than they would have with standard care but their quality of life was also much improved during this time. Targeted therapies, because they only kill cancer cells, and leave most healthy cells untouched, have greatly reduced side-effects overall, in contrast to standard chemotherapy and radiation treatments. The immediate increase in energy and well-being that our patients describe when they are placed on the right targeted therapy is remarkable! 

And CTOAM’s evidence-based Nutraceutical diet plans aid your body to make the most from your cancer treatment, before, during and after you receive it! Science is able to do so much more for cancer patients than conventional cancer care currently offers.

Make sure you’re making the most of what is possible, and let CTOAM help you get access to the treatments that will benefit you most.

Find out how targeted treatment is far more gentle on a person’s body than traditional chemo or radiation.

An older woman smiles into the camera.

Explore ALL Your Cancer Treatment Options with CTOAM

With CTOAM, there is so much more that can be done to bring you peace of mind and the confidence that you are getting the very best treatment possible, in your home town, and with the support of your public healthcare oncologist! We’ll make it happen. 

Join the many thousands of cancer patients around the world who have already benefited from precision oncology.

Hope is here, regardless of what you’ve been told, there almost certainly are more options for you – register for a Precision Second Opinion with CTOAM’s medical team today.

We are here to answer any questions you might have, so please reach out and contact us anytime for more information about precision oncology and how it can benefit you. 

CTOAM, Precision Oncology Specialists: The future of cancer treatment, now.

References for above data. Please contact us for more information.

(1) Douillard et al., (2013). Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med; 369:1023-1034.

(2) Robert et al., (2013). A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). Journal of Clinical Oncology; 31(15).

(3) Lin et al., (2015). Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol; 11

(4): 556–565. (4) Ershler, (2006). Capecitabine Monotherapy: Safe and Effective Treatment for Metastatic Breast Cancer. The Oncologist;11(4):325-335.

(5) Wagner et al., (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer; 107(4): 588–591.

(6) Tran et al., (2011). Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer;117(20):4623-32.

Published by on April 18, 2018
Tags: , , ,


  • Nina Elliott says:

    I was diagnosed two years ago, at the age of 64 with non-Hodgkin lymphoma (mantle cell lymphoma) I had six intense chemo treatments with the hope of having a stem cell transplant but I did not produce any cells for the procedure. I am at home with a maintance drug Rituximab every three months for two years. I have faith in my doctors treatment for me but when I read postings like these I wonder if there is anything else out there to give me a longer survival rate or is this treatment adequate for my type of cancer.

    • CTOAM says:

      Hi Nina,

      Thank you so much for writing and we are very sorry to hear about your diagnosis. While cytotoxic chemotherapy and stem cell transplants have been the mainstays for treatment of lymphomas, there have been many advances in the areas of targeted and immune-based treatments. These have been leading to significant increases in survival rates and huge reductions in harmful side effects.

      One class of drugs is the Bruton tyrosine kinase inhibitors (BTKs), like Acalabrutinib. In a recent trial of heavily pre-treated refractory stage IV patients, Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. At a median follow-up of 15.2 months, responses were achieved in 81% of patients, including a complete response in 40%. Kaplan-Meier estimates of median durations of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72%, 67%, and 87%, respectively.

      In another trial using an older BTK inhibitor Ibrutinib in heavily pre-treated refractory stage IV patients, at 3.5 years of follow-up, the median progression-free and survival overall were 13 months and 33.6 months in patients with one prior line of therapy. The median progression-free survival in patients achieving a complete response was 46.2 months, and the duration of response in these patients was 55.7 months. Overall, 53%, 45%, and 37% of patients were alive at 2, 3, and 5 years, respectively, and the median overall survival was 26.7 months.

      While these impressive results are not possible with standard chemotherapy, improved efficacy can often be obtained using combination therapies. For example, data from the chemotherapy-free triple combination of Umbralisib, an oral, next generation PI3K delta inhibitor; Ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody; and Ibrutinib, resulted in a 100% overall response rate (ORR), including 50% complete remission (CR) rate in patients with mantle cell lymphoma.

      There are other such examples, including Lenalidomide plus Rituximab, which is highly active in initial treatment of mantle cell lymphoma.

      However, as with all cancers, the key is to determine the molecular and genetic mutations that are driving your own unique form of cancer. This is done using tumour DNA sequencing. Then we go ahead and target your specific genetic mutations with the FDA approved drugs that are designed for those exact mutations.

      Does that help to answer your question? Please feel free to ask us anything else.

  • Lloyd kipling says:

    Drs have advised that I have 6spots on my liver and radiation will not be the best choice for joe,help.drs have given me months to live.help.

Leave a Reply